Moreover, p-T181-tau levels are significantly higher in NDEVs isolated from later stage AD patients than from when they were still diagnosed with MCI [41], implicating either a disruption in the clearance capabilities or an enhancement in pathogenicity of EVs in later disease states. The gene discussed is MAPT; the disease is Alzheimer disease.